JPWO2022250070A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022250070A5 JPWO2022250070A5 JP2023523496A JP2023523496A JPWO2022250070A5 JP WO2022250070 A5 JPWO2022250070 A5 JP WO2022250070A5 JP 2023523496 A JP2023523496 A JP 2023523496A JP 2023523496 A JP2023523496 A JP 2023523496A JP WO2022250070 A5 JPWO2022250070 A5 JP WO2022250070A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- ubenimex
- group
- ctla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021089984 | 2021-05-28 | ||
| PCT/JP2022/021320 WO2022250070A1 (ja) | 2021-05-28 | 2022-05-25 | ウベニメクスと免疫チェックポイント阻害剤の併用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022250070A1 JPWO2022250070A1 (https=) | 2022-12-01 |
| JPWO2022250070A5 true JPWO2022250070A5 (https=) | 2025-05-20 |
Family
ID=84229856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023523496A Pending JPWO2022250070A1 (https=) | 2021-05-28 | 2022-05-25 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240082196A1 (https=) |
| EP (1) | EP4349362A4 (https=) |
| JP (1) | JPWO2022250070A1 (https=) |
| KR (1) | KR20240016267A (https=) |
| CN (1) | CN117412762A (https=) |
| AU (1) | AU2022280511A1 (https=) |
| CA (1) | CA3220025A1 (https=) |
| TW (1) | TW202313091A (https=) |
| WO (1) | WO2022250070A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| BR112018017195A2 (pt) | 2016-02-24 | 2019-01-02 | Children's Hospital Of Eastern Ontario Research Institute Inc. | terapia de combinação de smc para o tratamento do câncer |
| WO2018112364A1 (en) * | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating melanoma |
| AU2018241944A1 (en) | 2017-03-31 | 2019-08-15 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
| CA3060935A1 (en) * | 2017-05-01 | 2018-11-08 | The Children's Medical Center Coporation | Methods and compositions relating to anti-pd1 antibody reagents |
| WO2019122941A1 (en) | 2017-12-21 | 2019-06-27 | Debiopharm International Sa | Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule |
| JP2021517589A (ja) * | 2018-03-12 | 2021-07-26 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | 癌の治療のための化学免疫療法を増強するためのカロリー制限模倣物の使用 |
| ES3063234T3 (en) * | 2019-12-20 | 2026-04-15 | Formycon Ag | Formulations of anti-pd1 antibodies |
-
2022
- 2022-05-25 EP EP22811340.3A patent/EP4349362A4/en active Pending
- 2022-05-25 CA CA3220025A patent/CA3220025A1/en active Pending
- 2022-05-25 KR KR1020237040875A patent/KR20240016267A/ko active Pending
- 2022-05-25 WO PCT/JP2022/021320 patent/WO2022250070A1/ja not_active Ceased
- 2022-05-25 CN CN202280037979.2A patent/CN117412762A/zh active Pending
- 2022-05-25 AU AU2022280511A patent/AU2022280511A1/en active Pending
- 2022-05-25 JP JP2023523496A patent/JPWO2022250070A1/ja active Pending
- 2022-05-27 TW TW111119886A patent/TW202313091A/zh unknown
-
2023
- 2023-11-27 US US18/519,225 patent/US20240082196A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12201686B2 (en) | Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound | |
| JPWO2016204193A1 (ja) | 抗がん剤 | |
| TW201914592A (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| US20250281514A1 (en) | Treatment of cancer patients having kras mutations | |
| KR20160050026A (ko) | 항 종양제 및 항 종양 효과 증강제 | |
| JP2021511344A5 (https=) | ||
| JPWO2022250070A5 (https=) | ||
| CN115702930A (zh) | 一种用于乳腺癌、黑色素瘤和/或结直肠癌联合免疫治疗的药物组合物及其应用 | |
| CA3141174A1 (en) | Quinoline derivatives for treatment of head and neck cancer | |
| TWI671072B (zh) | 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合 | |
| US11311619B2 (en) | Integrin activator vaccine compositions | |
| TW201929900A (zh) | Ｐｄ－１抗體和阿帕替尼聯合治療三陰性乳腺癌的用途 | |
| JPWO2022177877A5 (https=) | ||
| Ueda et al. | Sidedness of the primary tumor on the effect of TAS-102 for refractory metastatic colorectal cancer | |
| HK40015395A (en) | Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator | |
| WO2024135809A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| CN111821304A (zh) | 酪氨酸激酶抑制剂联合长春碱类药物在制备预防或治疗肿瘤疾病的药物中的用途 | |
| WO2022270523A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| WO2022171064A1 (zh) | 烟酰胺及含有其的组合物的制药用途 | |
| CN121001749A (zh) | 药物偶联物治疗肿瘤疾病的用途及方法 | |
| WO2025082356A1 (zh) | Cldn18_2抗体与化学治疗药物的组合及其应用 | |
| WO2020083338A1 (zh) | 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途 | |
| Noh et al. | Anti-Cancer Activity of As4O4, and its Efficacy in a Series of Patient-Derived Xenografts for Human | |
| JPWO2022223784A5 (https=) | ||
| EP3288585A2 (en) | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |